[Federal Register Volume 71, Number 61 (Thursday, March 30, 2006)]
[Notices]
[Page 16169]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 06-3096]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Notice of Establishment

    Pursuant to the Federal Advisory Committee Act, as amended (5 
U.S.C. Appendix 2), the Director, National Institutes of Health (NIH), 
announces the establishment of the National Cancer Institute Clinical 
Trials Advisory Committee (Committee).
    This Committee shall advise the Director, NCI, NCI Deputy 
Directors, and the Director of each NCI Division on the NCI-support 
national clinical trials enterprise to build a strong scientific 
infrastructure by bringing together a broadly developed and engaged 
coalition of stakeholders involved in the clinical trials process.
    The Committee will consist of 25 members, including the Chair, 
appointed by the Director, NCI. Members shall be authorities 
knowledgeable in the fields of community, surgical, medical, and 
radiation oncology, patient advocacy, extramural clinical 
investigation, regulatory agencies, pharmaceutical industry, public 
health, clinical trials design, management and evaluation, drug 
development and developmental therapeutics, cancer prevention and 
control research in the fields of interest to NCI.
    Duration of this committee is continuing unless formally determined 
by the Director, NCI that termination would be in the best public 
interest.

    Dated: March 21, 2006.
Elias A. Zerhouni,
Director, National Institutes of Health.
[FR Doc. 06-3096 Filed 3-29-06; 8:45 am]
BILLING CODE 4140-01-M